Biotech and Autoloops Forge Partnership for Advancing CAR-T Cell Therapy Pipeline and Scaling Late-Stage Initiatives
BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (Nasdaq: AUTL, “Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T…
RSVVW Abstract Regarding mRNA-1345: Official Statement
At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345. As previously published…
Takeda Plans Prompt Commencement of Global Phase 3 Trials for TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 by First Half of Fiscal Year 2024
Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with…
Positive Results for Mosunetuzumab in Japanese Phase I Study: Meeting Primary Endpoint for Relapsed and Refractory Follicular Lymphoma Expansion Cohort
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion…
Crovalimab Becomes First Country Approved in China for Treating Paroxysmal Nocturnal Haemoglobinuria
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced today the approval of crovalimab (known as 派圣凯® in China), a humanized complement inhibitor C5 monoclonal antibody developed by Chugai, by the…
Michael Kleinemeier to Serve as Chairman of Merck’s Supervisory Board until the 2024 Annual General Meeting
Merck, a renowned science and technology enterprise, has announced the appointment of Michael Kleinemeier (66) as the Chair of its Supervisory Board. Kleinemeier, who previously served as a member of…
Sanofi’s Scientific Leadership in Inflammatory Diseases Showcased with New Data at AAAAI Presentation
Sanofi’s Leading Role in Addressing Inflammatory Diseases Highlighted at AAAAI Conference The latest data presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting sheds light on…
Lilly Treasurer Philip Johnson Announces Retirement
Eli Lilly and Company (NYSE:LLY) has announced that Philip Johnson, the group vice president and treasurer, will be retiring from the company after more than 28 years of service. His…
Recent Data Reveals Nexviazyme® Exhibits Clinical Safety, Benefits, and Long-lasting Efficacy Across Diverse Pompe Disease Patient Cohorts
New data indicate that treatment with Nexviazyme® (avalglucosidase alfa) has significantly improved ptosis, or drooping eyelid, in pediatric patients with infantile-onset Pompe disease (IOPD) over nearly three years. These findings,…
Addressing Disparities in Cancer Care: American Cancer Society and Pfizer Unveil a $15 Million, Three-Year Initiative to Overcome Barriers
The American Cancer Society (ACS) and Pfizer Inc. (NYSE: PFE) have jointly unveiled the “Change the Odds: Uniting to Improve Cancer Outcomes™” initiative, a three-year program aimed at addressing disparities…
Novartis Enhances Oncology Portfolio Through Acquisition of MorphoSys AG at EUR 68 Per Share, Totaling EUR 2.7 Billion in Cash
Novartis has announced its intent to initiate a voluntary public takeover offer for the acquisition of MorphoSys AG (FSE: MOR; NASDAQ: MOR), a global biopharmaceutical company headquartered in Germany, specializing…
Acquisition of Elanco’s Aqua Business by Merck Animal Health
Merck Animal Health, operating as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, N.J., USA, has officially…